stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) EV/FCF
As of 5 November 2026, iRhythm Holdings, Inc. (IRTC) trades at a EV/FCF of 598×. Over the past ten years it has ranged from −262× (January 2021) to 615× (November 2026); the current reading is higher than 100% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 167× | — |
| FY2024 | −96.1× | — |
| FY2023 | −33.2× | — |
| FY2022 | −50.1× | — |
| FY2021 | −49.1× | — |
| FY2020 | −230× | — |
| FY2019 | −38.2× | — |
| FY2018 | −47.2× | — |
| FY2017 | −66.8× | — |
| FY2016 | −4.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 524× | 412.25% |
| Jun 2026 | 102× | (51.46%) |
| Mar 2026 | 211× | 26.28% |
| Dec 2025 | 167× | (3.95%) |
| 40 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HAE Haemonetics Corporation compare | 20.9× |
| LIVN LivaNova PLC compare | 36.0× |
| UFPT UFP Technologies, Inc. compare | 38.7× |
| TXG 10x Genomics compare | 58.9× |
| TMDX TransMedics Group, Inc. compare | 62.5× |
| NEOG Neogen Corporation compare | 63.4× |
| ITGR Integer Holdings Corporation compare | 68.9× |
| AXGN AxoGen, Inc. compare | 118× |
| IRTC iRhythm Holdings, Inc. | 598× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement